

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030.

SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED, UNDER CLAUSE 41 OF THE LISTING AGREEMENT

(Rs. lakhs)

Unaudited			Audited	
3 months ended 31.12.2007	3 months ended 31.12.2006		Year ended 31.12.2007	Year ended 31.12.2006
		1. Segment Revenue:		
33504	29898	a) Pharmaceuticals	148531	139019
1122	3054	b) Other Businesses	11021	18134
34626	32952	Total Segment Revenue	159552	157153
-	-	Less: Inter Segment Revenue	-	-
34626	32952	Net Sales / Income from Operations	159552	157153
		2. Segment Results (Profit before Interest and Tax):		
10812	9343	a) Pharmaceuticals	54874	49211
300	844	b) Other Businesses	2165	3848
11112	10187	Total Segment Results	57039	53059
		Add/(Less):		
1082	1007	(i) Interest Income (net)	4523	3426
(646)	(749)	(ii) Un-allocable Expenditure	(3068)	(2597)
1059	278	(iii) Un-allocable Income	2624	1707
12607	10723	Total Profit Before Tax and Exceptional Items	61118	55595
		3. Capital Employed (Segment Assets less Segment Liabilities):		
13285	15849	a) Pharmaceuticals	13285	15849
1909	6040	b) Other Businesses	1909	6040
120898	97583	c) Unallocated	120898	97583
136092	119472	Total	136092	119472

Notes: [1] Refer notes 1, 2, 4, 7 and 8 of the aforesaid audited financial results for the year ended 31st December, 2007. [2] (i) The above segment disclosures comprise of two main business segments, namely: • Pharmaceuticals - comprising of bulk drugs and formulations; • Others - primarily comprising of fine chemicals, diagnostics, laboratory equipment and exports mainly relating to pharmaceuticals. Animal Health business formed part of the Company's Other Businesses segment in the previous year.

Segments have been identified and reported taking into account, the nature of products and services, the differing risks and returns, the organisation structure, and the internal financial reporting systems. (ii) Segment Revenue in each of the above domestic business segments primarily includes sales (net of excise duty), processing charges, consignment sales commission, clinical research and data management (net) and export incentives in the respective segments. (iii) Segment Revenue, Results, Assets and Liabilities include the respective amounts identifiable to each of the segments and amounts allocated on a reasonable basis.